The estimated Net Worth of Kenneth E Thorpe is at least $642 Thousand dollars as of 22 August 2016. Kenneth Thorpe owns over 1,450 units of Sanara MedTech stock worth over $588,101 and over the last 15 years he sold SMTI stock worth over $53,476. In addition, he makes $0 as Director at Sanara MedTech.
Kenneth has made over 1 trades of the Sanara MedTech stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,450 units of SMTI stock worth $53,476 on 22 August 2016.
The largest trade he's ever made was selling 1,450 units of Sanara MedTech stock on 22 August 2016 worth over $53,476. On average, Kenneth trades about 73 units every 0 days since 2010. As of 22 August 2016 he still owns at least 17,550 units of Sanara MedTech stock.
You can see the complete history of Kenneth Thorpe stock trades at the bottom of the page.
Dr. Kenneth E. Thorpe, Ph.D., is Director of the Company. He is the Robert W. Woodruff Professor and Chair of the Department of Health Policy & Management in the Rollins School of Public Health of Emory University in Atlanta, Georgia. Dr. Thorpe previously held health policy professorships at Tulane University, the University of North Carolina at Chapel Hill, Harvard University School of Public Health, and Columbia University. Dr. Thorpe was Deputy Assistant Secretary for Health Policy in the U.S. Department of Health and Human Services from 1993 to 1995 during the Clinton Administration.
Kenneth Thorpe is 61, he's been the Director of Sanara MedTech since 2019. There are 2 older and 4 younger executives at Sanara MedTech. The oldest executive at Sanara MedTech Inc. is Ronald T. Nixon, 65, who is the Exec. Chairman.
Kenneth's mailing address filed with the SEC is 1200 SUMMIT AVE, SUITE 414, FORT WORTH, TX, 76102.
Over the last 5 years, insiders at Sanara MedTech have traded over $168,795 worth of Sanara MedTech stock. The most active insiders traders include Eric D Tanzberger, Ronald T Nixon, and James W Stuckert. On average, Sanara MedTech executives and independent directors trade stock every 55 days with the average trade being worth of $25,133. The most recent stock trade was executed by Michael D. Mc Neil on 12 April 2023, trading 1,000 units of SMTI stock currently worth $6,000.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech executives and other stock owners filed with the SEC include: